Atrin

Atrin Pharmaceuticals is a privately held biopharmaceutical company pioneering the discovery and development of proprietary molecules targeting the DNA Damage and Response (DDR) pathway to treat a broad range of cancers associated with synthetic lethality and deregulated DNA damage response. Atrin targets the DDR pathway to develop novel drugs for a wide range of cancer patients through selective synthetic lethal interactions.